2022 Q4 Form 10-Q Financial Statement

#000165495422015282 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $1.026M $869.7K $159.5K
YoY Change 310.57% 445.3% -155.27%
Cost Of Revenue $98.71K $86.50K $53.93K
YoY Change 238.38% 60.39% 114.01%
Gross Profit $927.7K $783.2K $105.6K
YoY Change 320.1% 641.97% -133.64%
Gross Profit Margin 90.38% 90.05% 66.18%
Selling, General & Admin $3.174M $3.509M $3.837M
YoY Change -4.32% -8.54% 64.55%
% of Gross Profit 342.17% 448.04% 3634.81%
Research & Development $4.368M $6.027M $3.485M
YoY Change -19.51% 72.95% 19.18%
% of Gross Profit 470.79% 769.59% 3301.53%
Depreciation & Amortization $69.77K $59.63K $12.56K
YoY Change 152.88% 374.76% -6.58%
% of Gross Profit 7.52% 7.61% 11.9%
Operating Expenses $6.613M $9.622M $7.375M
YoY Change -24.62% 30.47% 101.68%
Operating Profit -$5.587M -$8.753M -$7.216M
YoY Change -33.89% 21.3% 82.89%
Interest Expense $5.487K $9.602K $5.631K
YoY Change 97.87% 70.52% -24.81%
% of Operating Profit
Other Income/Expense, Net -$512.2K $497.3K $103.1K
YoY Change 117.71% 382.13% 2119.93%
Pretax Income -$6.099M -$8.255M -$7.113M
YoY Change -29.79% 16.07% 80.49%
Income Tax -$4.675M
% Of Pretax Income
Net Earnings -$1.424M -$8.255M -$7.113M
YoY Change -83.61% 16.07% 80.49%
Net Earnings / Revenue -138.74% -949.28% -4459.88%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.13 -$856.8K -$29.86K
COMMON SHARES
Basic Shares Outstanding 10.35M shares 9.290M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.18M $21.19M $53.42M
YoY Change -55.24% -60.33% -38.3%
Cash & Equivalents $21.18M $21.19M $53.42M
Short-Term Investments
Other Short-Term Assets $2.127M $2.105M $2.947M
YoY Change -10.61% -28.57% 24.86%
Inventory $759.3K $858.0K $1.108M
Prepaid Expenses
Receivables $1.807M $2.023M $914.0K
Other Receivables $4.675M $0.00 $0.00
Total Short-Term Assets $30.55M $26.18M $58.39M
YoY Change -40.52% -55.17% -41.48%
LONG-TERM ASSETS
Property, Plant & Equipment $674.6K $620.9K $140.0K
YoY Change 31.93% 343.44% -89.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $56.92K $56.92K $56.92K
YoY Change 0.0% 0.0% -0.01%
Total Long-Term Assets $1.425M $1.465M $1.343M
YoY Change -12.37% 9.03% -2.24%
TOTAL ASSETS
Total Short-Term Assets $30.55M $26.18M $58.39M
Total Long-Term Assets $1.425M $1.465M $1.343M
Total Assets $31.98M $27.64M $59.73M
YoY Change -39.66% -53.72% -40.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $820.3K $3.774M $762.8K
YoY Change 412.11% 394.8% -21.47%
Accrued Expenses $6.066M $6.117M $4.991M
YoY Change -1.82% 22.55% 21.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $103.6K $102.3K
YoY Change 6.91%
Total Short-Term Liabilities $11.42M $15.86M $9.788M
YoY Change -17.63% 62.05% -22.64%
LONG-TERM LIABILITIES
Long-Term Debt $99.91K $126.3K $0.00
YoY Change -51.24%
Other Long-Term Liabilities $3.733M $2.740M $6.168M
YoY Change 23.87% -55.57% -46.51%
Total Long-Term Liabilities $3.733M $2.740M $6.168M
YoY Change 23.87% -55.57% -46.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.42M $15.86M $9.788M
Total Long-Term Liabilities $3.733M $2.740M $6.168M
Total Liabilities $15.63M $19.19M $16.76M
YoY Change -12.17% 14.49% -30.68%
SHAREHOLDERS EQUITY
Retained Earnings -$397.7M -$396.2M -$358.9M
YoY Change 8.18% 10.4%
Common Stock $103.5K $92.91K $2.313M
YoY Change -95.53% -95.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.34M $8.449M $42.97M
YoY Change
Total Liabilities & Shareholders Equity $31.98M $27.64M $59.73M
YoY Change -39.66% -53.72% -40.95%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$1.424M -$8.255M -$7.113M
YoY Change -83.61% 16.07% 80.49%
Depreciation, Depletion And Amortization $69.77K $59.63K $12.56K
YoY Change 152.88% 374.76% -6.58%
Cash From Operating Activities -$8.824M -$24.73K -$6.424M
YoY Change 40.31% -99.61% -268.47%
INVESTING ACTIVITIES
Capital Expenditures $123.4K -$141.2K -$57.76K
YoY Change -238.53% 144.51%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$123.4K -$141.2K -$57.76K
YoY Change 38.53% 144.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.938M -$8.581M -$202.4K
YoY Change 3066.69% 4140.77% 160.21%
NET CHANGE
Cash From Operating Activities -8.824M -$24.73K -$6.424M
Cash From Investing Activities -123.4K -$141.2K -$57.76K
Cash From Financing Activities 8.938M -$8.581M -$202.4K
Net Change In Cash -9.040K -$8.747M -$6.684M
YoY Change -99.85% 30.87% -278.94%
FREE CASH FLOW
Cash From Operating Activities -$8.824M -$24.73K -$6.424M
Capital Expenditures $123.4K -$141.2K -$57.76K
Free Cash Flow -$8.947M $116.5K -$6.366M
YoY Change 44.31% -101.83% -266.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
260957 usd
CY2021Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
398812 usd
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4030 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9290504 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9270947 shares
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
86496 usd
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
53933 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6027031 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3484764 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3508798 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3836542 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
497263 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
103138 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8255408 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7112619 usd
CY2022Q3 ptn Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
86 shares
CY2021Q3 ptn Basic And Diluted Net Loss Per Common Share
BasicAndDilutedNetLossPerCommonShare
75 shares
CY2022Q3 ptn Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Common Share Note1
WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerCommonShareNote1
9634684
CY2021Q3 ptn Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted Net Loss Per Common Share Note1
WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDilutedNetLossPerCommonShareNote1
9529322
CY2022Q3 ptn Profits Loss
ProfitsLoss
8255408 usd
CY2021Q3 ptn Profits Loss
ProfitsLoss
7112619 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59625 usd
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12559 usd
CY2021Q3 ptn Decrease In Right Of Use Asset
DecreaseInRightOfUseAsset
91481 usd
CY2022Q3 ptn Unrealized Foreign Currency Transaction Gain Loss
UnrealizedForeignCurrencyTransactionGainLoss
418376 usd
CY2021Q3 ptn Unrealized Foreign Currency Transaction Gain Loss
UnrealizedForeignCurrencyTransactionGainLoss
107359 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
436877 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
632727 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-242730 usd
CY2021Q3 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
666428 usd
CY2022Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-172401 usd
CY2021Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
112882 usd
CY2022Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
86496 usd
CY2022Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
682920 usd
CY2021Q3 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
122167 usd
CY2022Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-758375 usd
CY2021Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-806214 usd
CY2022Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-91682 usd
CY2021Q3 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89608 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-8581320 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6423623 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57764 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-141228 usd
CY2022Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 usd
CY2021Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
202353 usd
CY2022Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
24731 usd
CY2021Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0 usd
CY2022Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24731 usd
CY2021Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-202353 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8747279 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-6683740 usd
CY2022Q3 us-gaap Interest Paid Net
InterestPaidNet
9602 usd
CY2021Q3 us-gaap Interest Paid Net
InterestPaidNet
5631 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396249104 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8255408 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21191875 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15861001 usd
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
21057025 usd
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
29740565 usd
CY2022Q2 ptn Vyleesi Contractual Advances
VyleesiContractualAdvances
815750 usd
CY2022Q2 ptn Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
310573 usd
CY2020Q3 ptn Contract Termination Agreement Payments
ContractTerminationAgreementPayments
12000000 usd
CY2021Q1 ptn Contract Termination Agreement Payments
ContractTerminationAgreementPayments
4300000 usd
CY2022Q3 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
18194000 usd
CY2022Q3 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
2300000 usd
CY2020Q3 ptn Inventory And Prepaid Expenses Estimated Fair Value
InventoryAndPrepaidExpensesEstimatedFairValue
5817795 usd
CY2020Q3 ptn Gain On License Termination Agreement
GainOnLicenseTerminationAgreement
1623795 usd
CY2021Q2 us-gaap Loss On Contract Termination
LossOnContractTermination
4407987 usd
CY2021Q2 ptn Net Loss
NetLoss
2784192 usd
CY2022Q2 ptn Prepaid Insurance Premiums
PrepaidInsurancePremiums
132413 usd
CY2022Q3 ptn Agreement With Fosun
AgreementWithFosun
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>(7) AGREEMENT WITH FOSUN</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On September 6, 2017, the Company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (“Fosun”) for exclusive rights to commercialize Vyleesi in China (the “Fosun License Agreement”). Under the terms of the agreement, the Company received $4,500,000 in October 2017, which consisted of an upfront payment of $5,000,000 less $500,000 that was withheld in accordance with tax withholding requirements in China and recorded as an expense during the year ended June 30, 2018. The Company is entitled to receive a $7,500,000 milestone payment when regulatory approval in China is obtained, provided that a commercial supply agreement for Vyleesi has been entered into. The Company has the potential to receive up to $92,500,000 in additional sales related milestone payments and high single-digit to low double-digit royalties on net sales in the licensed territory. All development, regulatory, sales, marketing, and commercial activities and associated costs in the licensed territory will be the sole responsibility of Fosun. </p>
CY2017Q3 us-gaap Increase Decrease In Deferred Revenue And Customer Advances And Deposits
IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits
4500000 usd
CY2017Q3 us-gaap Payments For Restructuring
PaymentsForRestructuring
5000000 usd
CY2017Q3 ptn Taxexpenses
taxexpenses
500000 usd
CY2017Q3 us-gaap Payments To Acquire Receivables
PaymentsToAcquireReceivables
7500000 usd
CY2017Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
92500000 usd
CY2017Q4 us-gaap Officers Compensation
OfficersCompensation
417500 usd
CY2017Q4 us-gaap Payments For Restructuring
PaymentsForRestructuring
500000 usd
CY2017Q4 ptn Taxexpenses
taxexpenses
82500 usd
CY2017Q4 us-gaap Payments To Acquire Receivables
PaymentsToAcquireReceivables
3000000 usd
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
37500000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
1932454 usd
CY2022Q2 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
29740565 usd
CY2022Q2 ptn Clinical Study Costs
ClinicalStudyCosts
3944798 usd
CY2022Q2 ptn Other Research Related Expenses
OtherResearchRelatedExpenses
35172 usd
CY2022Q2 ptn Personal Cost
PersonalCost
1545896 usd
CY2022Q2 ptn Accrued Selling Expenses
AccruedSellingExpenses
840703 usd
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157390 usd
CY2022Q2 ptn Tota Acrrued Liabilities
TotaAcrruedLiabilities
6875216 usd
CY2022Q3 us-gaap Advances On Inventory Purchases
AdvancesOnInventoryPurchases
9125648 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5754986 usd
CY2022Q2 ptn Accrued Other Long Term Liabilities
AccruedOtherLongTermLiabilities
2861250 usd
CY2022Q3 ptn Voting Of Shares Description
VotingOfSharesDescription
The holders of Series C Preferred Stock were entitled to 20,000 votes per share of common stock
CY2022Q3 ptn Number Of Shares Issued
NumberOfSharesIssued
40000000 shares
CY2022Q3 ptn Decription Of Commission
DecriptionOfCommission
The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2022Q3 ptn Shares Of Common Stock
SharesOfCommonStock
33333 shares
CY2022Q3 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
33333 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P7Y1M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1660 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.36
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4768 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.17
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17056 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.00
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1143798 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.95
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
685855 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.34
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
457943 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
12.38
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2022Q3 ptn Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees
UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees
166233 shares
CY2022Q3 ptn Unvested Performance Based Stock Options Granted
UnvestedPerformanceBasedStockOptionsGranted
18921 shares
CY2020Q2 ptn Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
87303 usd
CY2021Q2 ptn Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
95167 usd
CY2021Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
233915 usd
CY2021Q2 ptn Performance Based Restricted Stock
PerformanceBasedRestrictedStock
18000 shares
CY2022Q3 dei Entity Central Index Key
EntityCentralIndexKey
0000911216
CY2022Q3 dei Amendment Flag
AmendmentFlag
false
CY2022Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2022Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
4030 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4030 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9270947 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9290504 shares
CY2022Q2 us-gaap Related Party Transaction Purchases From Related Party
RelatedPartyTransactionPurchasesFromRelatedParty
1623795 usd
CY2022Q3 ptn License And Contract Revenue
LicenseAndContractRevenue
2500000 usd
CY2017Q4 ptn License Agreement
LicenseAgreement
94869 usd
CY2022Q2 us-gaap Contributions In Aid Of Construction
ContributionsInAidOfConstruction
220864 usd
CY2022Q3 us-gaap Contributions In Aid Of Construction
ContributionsInAidOfConstruction
168210 usd
CY2022Q3 dei Document Type
DocumentType
10-Q
CY2022Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q3 dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q3 dei Entity File Number
EntityFileNumber
001-15543
CY2022Q3 dei Entity Registrant Name
EntityRegistrantName
PALATIN TECHNOLOGIES, INC.
CY2022Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q3 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
95-4078884
CY2022Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
4B Cedar Brook Drive
CY2022Q3 dei Entity Address City Or Town
EntityAddressCityOrTown
Cranbury
CY2022Q3 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2022Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
08512
CY2022Q3 dei City Area Code
CityAreaCode
609
CY2022Q3 dei Local Phone Number
LocalPhoneNumber
495‑2200
CY2022Q3 dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
CY2022Q3 dei Trading Symbol
TradingSymbol
PTN
CY2022Q3 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2022Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q3 dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10353926 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21191875 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29939154 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2022750 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1780020 usd
CY2022Q3 us-gaap Inventory Net
InventoryNet
857975 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
944471 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2104855 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1932454 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
26177455 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
34596099 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
620917 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
539314 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
786731 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
878465 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56916 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
56916 usd
CY2022Q3 us-gaap Assets
Assets
27642019 usd
CY2022Q2 us-gaap Assets
Assets
36070794 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3774399 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3157617 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6116841 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6875216 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
343749 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
371124 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
102264 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
100921 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5523748 usd
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5754986 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15861001 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16259864 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
465091 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
529398 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
126333 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
152407 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2740250 usd
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2861250 usd
CY2022Q3 us-gaap Liabilities
Liabilities
19192675 usd
CY2022Q2 us-gaap Liabilities
Liabilities
19802919 usd
CY2022Q3 ptn Escrowed Proceeds
EscrowedProceeds
-15000000 usd
CY2022Q2 ptn Escrowed Proceeds
EscrowedProceeds
-15000000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
4030 shares
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
40 usd
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
40 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
92905 usd
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
92709 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
404605503 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
404168822 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-396249104 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-387993696 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8449344 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16267875 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27642019 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36070794 usd
CY2022Q3 ptn Product Revenue Net
ProductRevenueNet
869654 usd
CY2021Q3 ptn Product Revenue Net
ProductRevenueNet
159482 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9622325 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
7375239 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8752671 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7215757 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
88489 usd
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1410 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
418376 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
107359 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
9602 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
5631 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
16267875 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
436877 usd
CY2022Q3 ptn Reverse Stock Split Fractional Shares Amount
ReverseStockSplitFractionalSharesAmount
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8255408 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
8449344 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
49651372 usd
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
632727 usd
CY2021Q3 ptn Taxes Withheld Related To Restricted Stock Units Amount
TaxesWithheldRelatedToRestrictedStockUnitsAmount
-202353 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-7112619 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42969127 usd
CY2022Q3 ptn Decrease In Right Of Use Asset
DecreaseInRightOfUseAsset
91734 usd
CY2021Q3 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
53933 usd
CY2022Q3 ptn Purchases Of Property And Equipment
PurchasesOfPropertyAndEquipment
141228 usd
CY2021Q3 ptn Purchases Of Property And Equipment
PurchasesOfPropertyAndEquipment
57764 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29939154 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60104919 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21191875 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53421179 usd
CY2022Q3 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2690259 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2630634 usd
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2829183 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1317262 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
344180 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
269365 shares
CY2022Q3 ptn Prepaid Clinical Study Costs
PrepaidClinicalStudyCosts
446189 usd
CY2022Q3 ptn Prepaid Insurance Premiums
PrepaidInsurancePremiums
121000 usd
CY2022Q3 ptn Vyleesi Contractual Advances
VyleesiContractualAdvances
815750 usd
CY2022Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
721916 usd
CY2022Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
673718 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
2104855 usd
CY2022Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
21057025 usd
CY2022Q3 ptn Clinical Study Costs
ClinicalStudyCosts
4810130 usd
CY2022Q3 ptn Other Research Related Expenses
OtherResearchRelatedExpenses
255754 usd
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
129009 usd
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
351257 usd
CY2022Q3 ptn Personal Cost
PersonalCost
0 usd
CY2022Q3 ptn Accrued Selling Expenses
AccruedSellingExpenses
692968 usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
228980 usd
CY2022Q3 ptn Tota Acrrued Liabilities
TotaAcrruedLiabilities
6116841 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5523748 usd
CY2022Q3 ptn Accrued Other Long Term Liabilities
AccruedOtherLongTermLiabilities
2740250 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1163962 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.98
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
875 usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y8M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
875 usd
CY2022Q2 ptn Unvested Performances Based Restricted Stock Unit
UnvestedPerformancesBasedRestrictedStockUnit
60566 usd
CY2022Q3 us-gaap Restricted Stock Expense
RestrictedStockExpense
175920 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
649149 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
2608 shares
CY2022Q3 ptn Restricted Stock Vested In Period
RestrictedStockVestedInPeriod
-19600 shares
CY2022Q3 ptn Fractional Shares
FractionalShares
-6 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
626935 shares
CY2022Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
1020000 usd
CY2022Q4 ptn Pre Funded Warrants
PreFundedWarrants
798182 shares
CY2022Q4 ptn Purchase Of Common Stock
PurchaseOfCommonStock
1818182 shares
CY2022Q4 us-gaap Share Price
SharePrice
5.50
CY2022Q4 ptn Combined Offering Price
CombinedOfferingPrice
5.4999
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
5.83
CY2022Q4 ptn Pre Funded Warrants Exercise Price
PreFundedWarrantsExercisePrice
0.0001
CY2022Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9100000 usd
CY2022Q4 us-gaap Line Of Credit Facility Commitment Fee Percentage
LineOfCreditFacilityCommitmentFeePercentage
0.0499 pure
CY2022Q4 ptn Description Of Shareholder Ownership
DescriptionOfShareholderOwnership
any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder to the Company

Files In Submission

Name View Source Status
0001654954-22-015282-index-headers.html Edgar Link pending
0001654954-22-015282-index.html Edgar Link pending
0001654954-22-015282.txt Edgar Link pending
0001654954-22-015282-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptn-20220930.xsd Edgar Link pending
ptn_10q.htm Edgar Link pending
ptn_10qimg14.jpg Edgar Link pending
ptn_10qimg15.jpg Edgar Link pending
ptn_ex311.htm Edgar Link pending
ptn_ex312.htm Edgar Link pending
ptn_ex321.htm Edgar Link pending
ptn_ex322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
ptn-20220930_def.xml Edgar Link unprocessable
ptn-20220930_lab.xml Edgar Link unprocessable
ptn-20220930_pre.xml Edgar Link unprocessable
ptn_10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ptn-20220930_cal.xml Edgar Link unprocessable